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and Kai Hang Yiu2,4*Abstract
Background: Endothelial progenitor cells (EPCs) are responsible for angiogenesis and maintenance of
microvascular integrity, the number of EPCs is correlated with oxidative stress. Their relation to myocardial
dysfunction in patients with type 2 diabetes mellitus (T2DM) is nonetheless unknown.
Methods: Eighty-seven patients with T2DM and no history of coronary artery disease were recruited. Transthoracic
echocardiography and detailed evaluation of left ventricular (LV) systolic function by 2-dimensional (2D) speckle
tracking derived strain analysis in 3 orthogonal directions was performed. Four subpopulations of EPCs, including
CD34+, CD133+, CD34+/kinase insert domain-containing receptor (KDR) + and CD133+/KDR + EPCs, were measured
by flow cytometry. Oxidative stress was assessed by superoxide dismutase (SOD).
Results: The mean age of the patients was 62 ± 9 years and 39.6% were male. Those with an impaired longitudinal
strain had a lower number of CD34+ EPCs (2.82 ± 1.87% vs. 3.74 ± 2.12%, P < 0.05) than those with preserved
longitudinal strain. When compared with those with preserved circumferential strain, patients with an impaired
circumferential strain had a lower number of CD34+ EPCs (2.63 ± 1.80% vs. 3.87 ± 2.10%, P < 0.01) and SOD level
(0.13 ± 0.06U/ml vs. 0.20 ± 0.08U/ml, P < 0.01). Patients with an impaired radial strain nonetheless had a lower
number of CD34+ EPCs (2.62 ± 2.08% vs. 3.69 ± 1.99%, P < 0.05). Multivariate analysis demonstrated that only
impaired global circumferential strain remained significantly associated with CD34 + EPCs and SOD.
Conclusions: LV global circumferential strain was independently associated with number of CD34+ EPCs and SOD.
These findings suggest that myocardial dysfunction in patients with T2DM is related to depletion of EPCs and
increased oxidative stress.
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Type 2 diabetes mellitus (T2DM) is associated with
myocardial dysfunction, independent of underlying cor-
onary artery disease. Patients with T2DM have a 2–5
fold higher risk of developing heart failure than those
without [1,2]. Although the pathology of myocardial
dysfunction in these patients is unclear, it is likely* Correspondence: hftse@hkucc.hku.hk; khkyiu@hotmail.com
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microangiopathy, [4] and altered myocardial metabolism
and structure with fibrosis [5].
Increasing evidence is emerging to support the role of
endothelial progenitor cells(EPCs), [6] a subpopulation
of mononuclear cells that possess the ability for vascular
repair and neovascularization, in microangiopathy and
myocardial dysfunction in patients with T2DM [7,8]. In
addition, EPCs have been shown to be closely related
with oxidative stress, that also contributes to myocardial
dysfunction in these patients. Recent studies have
demonstrated that 2-dimensional (2D) speckle tracking
derived strain analysis is a sensitive method to detecttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ently normal left ventricular (LV) ejection fraction
[9,10]. Nevertheless the association of EPCs and oxida-
tive stress with LV myocardial function in patients with
T2DM has not been evaluated. The aim of the present
study is to determine the relationship of EPCs and oxi-
dative stress, as determined by superoxide dismutase
(SOD), to myocardial function measured by 2D speckle
tracking LV strain.Method
Study population
A total of 110 consecutive patients with T2DM as
defined by World Health Organization criteria and no
coronary artery disease were recruited at Queen Mary
Hospital from January 2008 to January 2010. Patients
were excluded if they had a documented history or clin-
ical symptoms and signs of macrovascular disease in-
cluding myocardial infarction, coronary artery disease,
stroke or peripheral vascular disease. Patients with
dilated cardiomyopathy, New York Heart Association
class III/IV heart failure, significant renal dysfunction
with creatinine level > 220 umol/L, liver failure or clin-
ical/biochemical evidence of concomitant inflammatory
disease or patients who declined to participate were also
excluded. As a result, 87 subjects were eligible for
this study. The current study is in compliance with the
Helsinki Declaration and has been approved by the
Hong Kong West Cluster Ethics Committee. All patients
had a written informed consent.Study design
Baseline demographic data and cardiovascular medica-
tions were recorded in all subjects. Hypertension was
defined as resting systolic or diastolic blood pressure ≥140
/90 mmHg on two occasions or the prescription of anti-
hypertensive medication. Hypercholesterolemia was
defined as fasting total plasma cholesterol level
≥4.9 mmol/L or the prescription of lipid-lowering medica-
tion [11]. Smoking status was recorded as ever-smoker
(past or current) or non-smoker. Body height, weight and
blood pressure were measured as previously described
[12]. Body-mass index (BMI) was calculated as kg/m2.
Fasting blood samples were obtained to measure serum
total cholesterol, triglyceride, low-density lipoprotein-
cholesterol (LDL-C), high-density lipoprotein-cholesterol
(HDL-C), glucose, HbA1c, creatinine, and high sensitivity
C-reactive protein (hs-CRP).
After mixing, samples were centrifuged at 3000 rpm
for 20 minutes and the supernatants frozen at −80°C
until assay. Oxidative stress was measured as superoxide
dismutase (SOD), a potent antioxidant enzyme [13].Flow cytometry
Four subpopulations of EPCs, including CD34+, CD133
+, CD34+/kinase insert domain-containing receptor
(KDR) + and CD133+/KDR + EPCs, were measured by
flow cytometry. Fluorescence-activated cell analysis was
performed to determine the number of EPCs as
described previously [14]. Briefly, 100 μl of peripheral
blood was incubated with a phycoerythrin-conjugated
monoclonal antibody against human KDR (Sigma, St
Louis, MO, USA), followed by a fluorescein isothio-
cyanate (FITC)-conjugated CD34 and CD133 antibody
(Beckman Coulter, Fullerton, CA, USA). FITC-labelled
anti-human CD45 antibody was used for differential gat-
ing during flow analysis. FITC-labelled IgG1a (Beckman
Coulter) and phycoerythrin-labelled IgG2b (Becton
Dickinson, Franklin Lakes, NJ, USA) served as the isoty-
pic control for colour compensation. Analysis was per-
formed with an automated fluorescence-activated cell
counter (Elite; Beckman Coulter) in which 1 000 000
events were counted. The absolute number of cells
expressing CD34+, CD133+, CD34/KDR + CD133/KDR
+ per 1 000 000 events in the lymphocyte gate was cal-
culated. The percentages of all the measured compo-
nents were derived from the absolute cell count divided
by the lymphocyte count [15].
Echocardiography
Transthoracic echocardiography was performed in
all patients using a commercially available system
(Vingmed Vivid 7, General Electric Vingmed Ultra-
sound, Milwaukee, USA). A 3.5-MHz transducer was
used to obtain images that were digitally stored in cine-
loop format (5 cardiac cycles). Measurements were per-
formed offline using EchoPAC version 108.1.5 (General
Electric – Vingmed, Horten, Norway). The inter-
ventricular septum thickness, posterior wall thickness,
and LV dimensions were measured in M-modal accord-
ing to the current recommendation. LV volume and
ejection fraction was determined from apical four and
two-chamber views using the modified Simpson’s bi-
plane method of discs. Evaluation of LV diastolic func-
tion was based on the pulsed-wave Doppler of mitral
valve inflow. Peak velocity in early diastole (E-wave) and
late diastole (A-wave) was measured and the E/A ratio
calculated. Pulsed wave tissue Doppler imaging was used
to measure the early diastolic velocity (E’) with the sam-
ple volume placed at lateral annulus. In addition, E/E’
ratio was calculated as an estimation of LV filling pres-
sure [16]. LV diastolic dysfunction was therefore classi-
fied as previously described [17].
Two-dimensional speckle tracking strain analysis
Two-dimensional speckle tracking strain analysis allows
detailed assessment of LV myocardial deformation by
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to-frame basis within the cardiac cycle. LV deformation
can be evaluated in three orthogonal directions as longi-
tudinal, circumferential and radial strains [18].
Longitudinal strain, assessing the shortening/lengthen-
ing of the myocardial wall, was measured from the 3 ap-
ical views: 2-chamber view (comprising anterior and
inferior walls), 4-chamber view (posteroseptal and lateral
walls) and long axis view (anteroseptal and posterior
walls). Each wall was subsequently divided into 3 levels
(basal, mid and apical) and a total of 18 segmental strain
curves were obtained. Global longitudinal strain was cal-
culated as the mean of the peak systolic strain value of
the 18 segments.
From LV mid-ventricular short-axis view, both circum-
ferential strain (evaluating myocardial shortening/length-
ening along LV curvature) and radial strain (evaluating
myocardial thickening/thinning) were measured. The
global value of circumferential and radial strains were
derived from the average peak systolic strain value of 6
segments. Global longitudinal and circumferential
strains are expressed as negative values, and a lower
strain is represented by less negative values. Global ra-
dial strain is expressed as a positive value: a lower value
indicates lower strain.
Impairment of the 3-orthogonal directional global
strains was defined as mean ± 2 standard deviations
according to the results of a recent study that assessed
global strains in healthy Asian subjects using the
same vendor machine as the current study [19]. Thus
in this study impaired global longitudinal strain is
defined as > −17.1%; impaired global circumferential
strain > −17.0% and; impaired radial strain <29.4%.
The interobserver and intraobserver variability for lon-
gitudinal, radial, and circumferential strains were 6.5%
and 2.6%, 10.4% and 7.6%, 4.9% and 2.4%, respectively.Statistical analysis
All continuous variables and categorical variables are
expressed as mean ± standard deviation and frequencies
or proportions, respectively. Continuous demographic
variables were compared using the Mann–Whitney U
test and categorical demographic variables were com-
pared using Pearson Chi-square test or the Fisher’s exact
test if at least one cell had an expected cell count below
five. Correlation coefficients were performed in order to
assess the association of circulating EPCs and oxidative
stress with myocardial function in T2DM patients.
Multivariate analyses were performed to detect the pre-
dictors for abnormal myocardial function. To avoid
multi-collinearity, multi-directional strains were entered
individually into the model. All statistical analyses were
performed using the statistical package SPSS forwindows (Version 18.0, SPSS, Chicago, USA). All P values
reported are 2-sided for consistency. A P value <0.05 was
considered statistically significant.
Results
Baseline characteristics
The baseline characteristics of all patients are shown in
Table 1. All patients had normal LV dimension and
function including LV end diastolic volume (mean 80 ±
19 ml), LV end systolic volume (30 ± 12 ml) and LV ejec-
tion fraction (64 ± 7%). Diastolic dysfunction was noted
in 69 patients (79%) and the mean E/E’ ratio was 9.9 ±
2.6. The mean global longitudinal, circumferential and
radial strains were 17.6 ± 2.5%, 17.7 ± 2.2% and 33.7 ±
11.0%, respectively. According to the pre-defined cut-off
values, 39% of patients had impaired global longitudinal
strain; 39% had impaired radial strain; and 30% had
impaired radial strain.
Clinical demographics in patients with and without
impaired strains
The clinical demographics of patients with and without
impaired LV strain are shown in Table 1. Patients with
an impaired longitudinal strain had a higher BMI,
HbA1c level and a lower number of CD34+ EPCs than
those with preserved longitudinal strain. When com-
pared with those with preserved circumferential strain,
patients with an impaired circumferential strain had a
lower CD34+ EPCs and SOD level. Patients with an
impaired radial strain nonetheless had a lower number
of CD34+ EPCs compared with those with preserved ra-
dial strain.
Correlation of global strains with clinical demographics
The correlation between the 3 orthogonal directional
strains and clinical demographics is shown in Table 2.
Global longitudinal and radial strains were both nega-
tively correlated with BMI. Global circumferential and
radial strains were correlated with CD34+ EPCs. Only
circumferential strain was negatively correlated
with serum level of SOD. In addition, level of CD34+
EPCs was significantly correlated with serum level of
SOD (R = 0.37, P < 0.01). Nonetheless CD133+ (R = 0.13,
P = 0.30), CD34+/KDR + (R = 0.09, P = 0.50) and CD133
+/KDR + EPCs (R = 0.11, P = 0.41) showed no such
correlation.
Association of endothelial progenitor cells and
superoxide dismutase with global strains
Univariate analysis revealed that impaired circumferen-
tial and radial strains were associated with CD34+ EPC
level and impaired global longitudinal, circumferential
and radial strains were related to SOD (Table 3). In
order to evaluate the relation of impaired global strains
Table 1 Clinical demographics in patients with and without impaired strains
Variables All patients
(n = 87)
Longitudinal strain
(cutoff −17.1%)
Circumferential strain
(cutoff −17.0%)
Radial strain
(cutoff 29.4%)
Preserved
(n = 53)
Impaired
(n = 34)
Preserved
(n = 53)
Impaired
(n = 34)
Preserved
(n = 62)
Impaired
(n = 25)
Age, years 61.8 ± 9.3 60.5 ± 9.7 63.9 ± 8.2 61.4 ± 10.1 62.5 ± 7.9 61.3 ± 9.7 62.9 ± 8.3
Male gender, % (n) 39.6(36) 42.9(24) 34.3(12) 33.9(19) 48.6(17) 59.7(37) 64.0(16)
BMI, kg/m2 25.7 ± 4.3 *25.01 ± 4.2 26.9 ± 4.2 25.3 ± 4.0 26.3 ± 4.7 25.2 ± 4.4 26.9 ± 4.2
SBP, mmHg 137 ± 16 137 ± 16 138 ± 16 138 ± 15 138 ± 17 136 ± 16 141 ± 16
DBP, mmHg 78 ± 8 78 ± 8 78 ± 8 77 ± 9 78 ± 7 77 ± 8 79 ± 8
Duration of disease, years 9.9 ± 7.7 8.9 ± 8.0 11.8 ± 7.0 8.9 ± 6.9 11.7 ± 8.9 10.4 ± 8.2 9.0 ± 7.2
Insulin therapy, % (n) 19.8(18) *37.1(13) 8.9(5) 19.6(11) 20.0(7) 17.7(11) 24.0(6)
Smoker, % (n) 17.6(16) 17.9(10) 17.1(6) 16.1(9) 20.0(7) 14.5(9) 20.0(5)
Hypertension, % (n) 60.4(55) 57.1(32) 65.7(23) 57.1(32) 65.7(23) 61.3(38) 52.0(13)
Total cholesterol, mmol/L 4.9 ± 0.8 5.02 ± 0.90 4.83 ± 0.73 5.01 ± 0.85 4.84 ± 0.82 4.97 ± 0.86 4.95 ± 0.78
Triglycerides, mmol/L 1.4 ± 0.8 1.36 ± 0.80 1.42 ± 0.75 1.43 ± 0.79 1.31 ± 0.77 1.32 ± 0.77 1.53 ± 0.81
High density lipoprotein, mmol/L 1.4 ± 0.4 1.39 ± 0.37 1.44 ± 0.45 1.40 ± 0.36 1.42 ± 0.45 1.42 ± 0.45 1.40 ± 0.24
Low density lipoprotein, mmol/L 2.9 ± 0.7 3.01 ± 0.75 2.72 ± 0.62 2.95 ± 0.70 2.83 ± 0.74 2.93 ± 0.71 2.86 ± 0.72
Fasting glucose, mmol/L 7.57 ± 2.07 7.19 ± 1.78 8.11 ± 2.34 7.49 ± 2.31 7.68 ± 1.68 7.68 ± 2.19 7.52 ± 1.70
Creatinine, umol/L 77.1 ± 25.1 76.8 ± 27.58 77.6 ± 21.1 77.3 ± 28.5 76.8 ± 19.0 74.1 ± 15.9 77.1 ± 23.6
hs-CRP, mg/L 1.49 ± 2.18 1.36 ± 1.75 1.72 ± 2.80 1.65 ± 2.71 1.27 ± 0.98 1.33 ± 1.68 1.90 ± 3.09
SOD, U/ml 0.17 ± 0.08 0.18 ± 0.09 0.15 ± 0.06 **0.20 ± 0.08 0.13 ± 0.06 0.17 ± 0.09 0.16 ± 0.08
HbA1c, % 7.72 ± 1.24 *7.51 ± 1.22 8.07 ± 1.20 7.70 ± 1.21 7.75 ± 1.30 7.83 ± 1.32 7.54 ± 1.00
CD34+ EPCs, % 3.38 ± 2.07 *3.74 ± 2.12 2.82 ± 1.87 **3.87 ± 2.10 2.63 ± 1.80 *3.69 ± 1.99 2.62 ± 2.08
CD133+ EPCs, % 0.44 ± 0.45 0.44 ± 0.47 0.45 ± 0.43 0.50 ± 0.49 0.35 ± 0.38 0.46 ± 0.47 0.41 ± 0.42
CD34+/KDR + EPCs, % 0.85 ± 0.69 0.89 ± 0.57 0.78 ± 0.85 0.92 ± 0.78 0.74 ± 0.52 0.91 ± 0.75 0.70 ± 0.49
CD133+/KDR + EPCs, % 0.25 ± 0.28 0.25 ± 0.30 0.25 ± 0.28 0.28 ± 0.32 0.21 ± 0.20 0.28 ± 0.32 0.19 ± 0.14
* P < 0.05; ** P < 0.01.
Abbreviations: BMI = body mass index; EPCs = endothelial progenitor cells; DBP = diastolic blood pressure; hs-CRP = High sensitivity C-reactive protein;
SBP = systolic blood pressure; SOD = superoxide dismutase.
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age, gender, BMI, smoking history, hypertension, hyper-
cholesterolaemia and HbA1c was performed. The results
demonstrated that impaired global circumferential and
radial strains were independently associated with CD34+
EPCs, whereas only impaired global circumferential
strain was independently associated with SOD. When
CD34+ EPCs and SOD were evaluated together,
impaired global circumferential strain was the only LV
strain that remained significantly associated with both
CD34 + EPCs (odd ratio [OR]. = 0.64, Confidence inter-
val [CI] = 0.43 - 0.95, P = 0.03) and SOD (OR = 0.001, CI
= 0.001 – 0.23, P = 0.02).
Discussion
The present study demonstrated that at least 30%
of T2DM patients, with apparently normal LV dimen-
sions and ejection fraction, have impaired myocardial
function as measured by 2D speckle tracking derived
strain. Importantly, LV global circumferential strain wasindependently associated with depletion of CD34+ EPCs
and increased oxidative stress measured by SOD.
Endothelial progenitor cells and myocardial dysfunction
The pathogenesis of myocardial dysfunction is multifa-
ceted, but includes activation of renin-angiotensin aldos-
terone system, [20] myocardial steatosis, [21] autonomic
dysfunction [22] and increased myocardial fibrosis [23].
Microangiopathy nonetheless has been proposed to con-
tribute to diabetic heart disease [24,25].
The presence of diabetes induces thickening of the
capillary basement membrane and endothelial swelling
of the myocardium [26,27]. These changes give rise
to microangiopathy as evidenced by microaneurysms,
interstitial fibrosis, and perfusion defect by radiological
study and finally result in myocardial dysfunction [28].
Preserving the integrity of the microvasculature, which
is partly maintained by circulating EPCs, may thus
prevent the development of diabetic heart disease.
In addition to endothelial regeneration and postnatal
Table 2 Correlation of the cardiovascular risk factors and global strains
Variables Longitudinal strain Circumferential strain Radial strain
R P value R P value R P value
Age 0.19 0.08 −0.01 0.92 −0.15 0.17
BMI 0.22 *0.04 0.19 0.09 −0.32 *0.003
SBP 0.08 0.44 0.08 0.50 −0.14 0.21
DBP 0.04 0.71 0.11 0.33 −0.12 0.30
Duration of disease 0.15 0.18 0.05 0.66 0.03 0.82
Total cholesterol −0.04 0.74 −0.08 0.48 −0.05 0.67
Triglycerides 0.13 0.23 −0.05 0.67 −0.15 0.18
High density lipoprotein −0.03 0.81 0.03 0.76 0.03 0.78
Low density lipoprotein −0.10 0.33 −0.09 0.42 0.07 0.95
Fasting glucose 0.10 0.38 0.07 0.57 0.01 0.92
Creatinine 0.08 0.48 0.16 0.14 −0.10 0.39
hs-CRP 0.05 0.72 −0.01 0.92 −0.22 0.09
SOD −0.23 0.07 −0.32 *0.01 0.11 0.39
HbA1c 0.07 0.50 −0.12 0.29 0.07 0.53
CD34+ ECPs −0.19 0.08 −0.28 *0.01 0.21 *0.049
CD133+ EPCs −0.02 0.86 −0.08 0.47 0.02 0.86
CD34+/KDR + EPCs −0.01 0.96 −0.21 0.05 0.18 0.10
CD133+/KDR + EPCs −0.07 0.54 −0.16 0.14 −0.02 0.87
Abbreviations: BMI = body mass index; EPCs = endothelial progenitor cells; DBP = diastolic blood pressure; hs-CRP = High sensitivity C-reactive protein; SBP =
systolic blood pressure; SOD = superoxide dismutase.
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differentiate into mature endothelial cells and be incor-
porated into new vessels enables EPCs to produce pro-
angiogenic cytokines in a paracrine fashion to facilitate
vascularization [29,30]. The clinical value of EPCs has
been established in diabetic patients, and their depletion
is associated with macrovascular disease such as
increased arterial stiffness, [31] carotid intima media
thickness, [32] brachial flow mediated dilatation [33]
and peripheral artery disease [34,35]. Depletion of EPCs
has also been shown to be predictive of future adverse
cardiovascular events [36,37]. A study by Yoon and col-
leagues has shown that DiI labelled bone marrow
derived EPCs contributed to myocardial microvascula-
ture and function in rats with diabetic heart disease [4].
No studies have evaluated the role of EPCs with myocar-
dial dysfunction in human subjects. The present study
further demonstrated that EPCs in patients with T2DM
and no atherosclerotic disease, were independently asso-
ciated with myocardial dysfunction, measured by 2D
speckle tracking strain. The current results thus suggest
that depletion of EPCs contributes to the development
of diabetic heart disease.
The present results indicate that CD34+ EPCs were
most strongly correlated with myocardial dysfunction,
compared with other subtypes of EPCs. Although the
reason is uncertain, this could be partly explained by theability of CD34+ EPCs to differentiate not only into
hematopoietic stem cells, but also cardiomyocytes,
smooth muscle and endothelial cells [38]. Previous stud-
ies have shown the CD34+ EPCs are best related with
cardiovascular risk factors, metabolic syndrome [39] and
long-term outcome compared with other subtypes
of EPCs [36]. The multi-lineage property of CD34+
EPCs may thus provide a more comprehensive assess-
ment of the pathophysiological development of diabetic
heart disease.
Oxidative stress and myocardial dysfunction
Oxidative stress, represented by an overproduction of re-
active oxygen species, plays a role in all stages of diabetic
heart disease, ranging from cardiac hypertrophy to myo-
cardial fibrosis and dysfunction [40]. Animal studies
have shown that suppression of oxidative stress with co-
enzyme A10 (an antioxidant in its reduced form, ubiqui-
nol-10) [41] and 30,40-dihydroxyflavonol (a synthetic
flavonol) [42], improves cardiac function and reduces
myocyte hypertrophy and collagen deposition in diabetic
rats. The present results further demonstrate the inde-
pendent role of SOD in relation to myocardial dysfunc-
tion, thus highlighting the role of oxidative stress in
the development of diabetic heart disease. In a study of
23 patients with T2DM, SOD has been proven to play
a role in modulating EPC function under hyperglycemic
Table 3 Unadjusted and adjusted effects of superoxide dismutase (SOD) and CD34+ endothelial progenitor cells (EPCs)
on global strains
Longitudinal strain Circumferential strain Radial strain
OR (95%) P value OR (95%) P value OR (95%) P value
SOD
Uadjusted 0.002(0.001,1.544) <0.01 0.001(0.001, 0.009) <0.01 0.02 (0.01, 17.22) 0.02
#Adjusted 0.001(0.000, 1.353) 0.060 0.002(0.001, 0.007) <0.01 0.004 (0.001, 7.868) 0.15
CD34+ EPCs
Uadjusted 0.81 (0.65, 1.02) 0.07 0.71 (0.55, 0.92) <0.01 0.75 (0.57, 0.98) 0.03
#Adjusted 0.82 (0.64-1.05) 0.12 0.71 (0.53, 0.93) 0.01 0.74 (0.56, 0.98) 0.04
CD133+ EPCs
Uadjusted 0.87 (0.35, 2.18) 0.76 0.44 (0.15, 1.32) 0.15 0.77 (0.26, 2.26) 0.77
#Adjusted 0.51 (0.18, 1.46) 0.21 0.38 (0.12, 1.20) 0.10 0.46 (0.14, 1.58) 0.22
CD34/KDR + EPCs
Uadjusted 0.79 (0.41, 1.51) 0.47 0.64 (0.30, 1.35) 0.24 0.56 (0.23, 1.37) 0.21
#Adjusted 0.71 (0.36, 1.42) 0.33 0.66 (0.30, 1.49) 0.32 0.50 (0.19, 1.33) 0.17
CD133/KDR + EPCs
Uadjusted 0.72 (0.17, 3.12) 0.66 0.34 (0.05, 2.17) 0.25 0.23 (0.02, 2.35) 0.21
#Adjusted 0.30 (0.06, 1.57) 0.15 0.26 (0.04, 1.79) 0.19 0.09 (0.01, 1.20) 0.07
Abbreviations: BMI = body mass index; EPCs = endothelial progenitor cells; DBP = diastolic blood pressure; hs-CRP = High sensitivity C-reactive protein; SBP =
systolic blood pressure; SOD = superoxide dismutase.
#Adjusted for age, gender, BMI, smoking, hypertension, hypercholesterolaemia, hbA1c.
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results of this study, suggesting the close interplay be-
tween oxidative stress and EPCs that independently con-
tributes to myocardial dysfunction.
Clinical implications
The present study is the first to demonstrate that
impaired myocardial function in patients with T2DM is
independently associated with depletion of EPCs and
increased oxidative stress. In animal studies, therapeutic
interventions aimed at increasing EPCs and reducing
oxidative stress improved myocardial function [4]. Fu-
ture human studies should therefore aim to develop
therapies that may reduce oxidative stress and/or recruit
EPCs to prevent myocardial dysfunction in patients
with T2DM.
Limitations
A causal relationship between CD34+ EPCs, SOD and
impaired myocardial strain could not be established
because of the cross-sectional nature of the study. Fur-
ther, although patients with T2DM were all clinically free
of cardiovascular complications, the presence of asymp-
tomatic coronary artery disease could not be excluded.
The small study population did not allow additional
analysis of other mechanisms that could potentially con-
tribute to myocardial dysfunction. In addition, the rea-
son for the correlation of CD34+ EPCs and SOD with
only global circumferential strain, not longitudinal andradial strains, is uncertain. The LV myocardial fibre
architecture has a typical orientation of myocardial
strands that change from being oblique in the subepicar-
dium, to circumferential in the middle, and longitudinal
in the subendocardium [44]. Thus, whether depletion of
CD34+ EPCs and oxidative stress preferentially affects
the mid-wall, rather than the subendocardium in these
patients, requires further evaluation.
Conclusions
Patients with T2DM and no clinical evidence of macro-
vascular disease showed impaired myocardial strain
detected by 2D speckle tracking derived strain analysis.
Importantly, LV global circumferential strain was inde-
pendently associated with both CD34+ EPCs and SOD.
These findings suggest that myocardial dysfunction in
patients with T2DM is related to depletion of EPCs and
increased oxidative stress.
Abbreviations
2D: 2-dimensional; BMI: Body-mass index; EPCs: Endothelial progenitor cells;
HDL-C: High-density lipoprotein-cholesterol; hs-CRP: High sensitivity C-
reactive protein; LDL-C: Low-density lipoprotein-cholesterol; LV: Left
ventricular; SOD: Superoxide dismutase; T2DM: Type 2 diabetes mellitus.
Competing interests
The authors declare that there is no competing interest associated with this
manuscript.
Authors’ contributions
CTZ coordinated analyses, interpreted results and wrote the manuscript. MW
performed statistical analyses and revised the manuscript. CWS advised and
Zhao et al. Cardiovascular Diabetology 2012, 11:147 Page 7 of 8
http://www.cardiab.com/content/11/1/147supervised statistical analyses and revised the manuscript. YLH and TW were
involved in the conception and design of the study, interpretation of the
data, ongoing support and advice to the first author. KHY contributed to
study design, data interpretation and manuscript revision. HFT designed and
led the project and revised the manuscript. All authors have approved the
final version of the manuscript.
Author details
1Shan Dong University School of Medicine, Shandong, China. 2Division of
Cardiology, Department of Medicine, the University of Hong Kong, Queen
Mary Hospital, Rm 1929b, Block K, Hong Kong, China. 3Division of Cardiology,
Traffic Hospital in Shan Dong Province, Shandong, China. 4Research Centre
of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine,
the University of Hong Kong, Hong Kong, China.
Received: 3 November 2012 Accepted: 27 November 2012
Published: 5 December 2012References
1. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB: The incidence of
congestive heart failure in type 2 diabetes: an update. Diabetes Care
2004, 27(8):1879–1884.
2. Kannel WB, Hjortland M, Castelli WP: Role of diabetes in congestive heart
failure: the Framingham study. Am J Cardiol 1974, 34(1):29–34.
3. Aksakal E, Akaras N, Kurt M, Tanboga IH, Halici Z, Odabasoglu F, Bakirci EM,
Unal B: The role of oxidative stress in diabetic cardiomyopathy: an
experimental study. Eur Rev Med Pharmacol Sci 2011, 15:1241–1246.
4. Yoon YS, Uchida S, Masuo O, Cejna M, Park JS, Gwon HC, Kirchmair R,
Bahlman F, Walter D, Curry C, et al: Progressive attenuation of myocardial
vascular endothelial growth factor expression is a seminal event in
diabetic cardiomyopathy: restoration of microvascular homeostasis and
recovery of cardiac function in diabetic cardiomyopathy after
replenishment of local vascular endothelial growth factor. Circulation
2005, 111(16):2073–2085.
5. Miki T, Yuda S, Kouzu H, Miura T: Diabetic cardiomyopathy:
pathophysiology and clinical features. Hear Fail Rev 2012, [epud ahead of
print].
6. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T,
Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor
endothelial cells for angiogenesis. Science 1997, 275:964–967.
7. Fadini GP, Mancuso P, Bertolini F, de Kreutzenberg S, Avogaro A:
Amelioration of glucose control mobilizes circulating pericyte progenitor
cells in type 2 diabetic patients with microangiopathy. Exp Diabetes Res
2012, Epud ahead of print.
8. Cheng Y, Guo S, Liu G, Feng Y, Yan B, Yu J, Feng K, Li Z: Transplantation of
bone marrow-derived endothelial progenitor cells attenuates myocardial
interstitial fibrosis and cardiac dysfunction in streptozotocin-induced
diabetic rats. Int J Mol Med 2012, Epud ahead of print.
9. Ernande L, Bergerot C, Rietzschel ER, De Buyzere ML, Thibault H,
Pignonblanc PG, Croisille P, Ovize M, Groisne L, Moulin P, et al: Diastolic
dysfunction in patients with type 2 diabetes mellitus: is it really the
first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr 2011,
24(11):1268–1275. e1261.
10. Ng AC, Delgado V, Bertini M, van der Meer RW, Rijzewijk LJ, Shanks M,
Nucifora G, Smit JW, Diamant M, Romijn JA, et al: Findings from left
ventricular strain and strain rate imaging in asymptomatic patients with
type 2 diabetes mellitus. Am J Cardiol 2009, 104:1398–1401.
11. Lau KK, Chan YH, Yiu KH, Li SW, Tam S, Lau CP, Kwong YL, Tse HF: Burden
of carotid atherosclerosis in patients with stroke: relationships with
circulating endothelial progenitor cells and hypertension. J Hum
Hypertens 2007, 21(6):445–451.
12. Luk TH, Dai YL, Siu CW, Yiu KH, Chan HT, Fong DY, Lee SW, Li SW, Tam S,
Lau CP, et al: Habitual physical activity is associated with endothelial
function and endothelial progenitor cells in patients with stable
coronary artery disease. Eur J Cardiovasc Prev Rehabil 2009, 16(4):464–471.
13. Dai YL, Luk TH, Yiu KH, Wang M, Yip PM, Lee SW, Li SW, Tam S, Fong B,
Lau CP, et al: Reversal of mitochondrial dysfunction by coenzyme Q10
supplement improves endothelial function in patients with ischaemic
left ventricular systolic dysfunction: a randomized controlled trial.
Atherosclerosis 2011, 216:395–401.14. Wong CY, Qiuwaxi J, Chen H, Li SW, Chan HT, Tam S, Shu XO, Lau CP,
Kwong YL, Tse HF: Daily intake of thiamine correlates with the circulating
level of endothelial progenitor cells and the endothelial function in
patients with type II diabetes. Mol Nutr Food Res 2008, 52(12):1421–1427.
15. Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, Lau CP, Lai WH, Wong LY,
Lam KF, Lau CS, et al: Role of circulating endothelial progenitor cells
in patients with rheumatoid arthritis with coronary calcification.
J Rheumatol 2010, 37(3):529–535.
16. McQuillan BM, Picard MH, Leavitt M, Weyman AE: Clinical correlates
and reference intervals for pulmonary artery systolic pressure
among echocardiographically normal subjects. Circulation 2001,
104(23):2797–2802.
17. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA,
Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A:
Recommendations for the evaluation of left ventricular diastolic function
by echocardiography. Eur J Echocardiogr 2009, 10(2):165–193.
18. Delgado V, Ypenburg C, van Bommel RJ, Tops LF, Mollema SA, Marsan NA,
Bleeker GB, Schalij MJ, Bax JJ: Assessment of left ventricular dyssynchrony
by speckle tracking strain imaging comparison between longitudinal,
circumferential, and radial strain in cardiac resynchronization therapy.
J Am Coll Cardiol 2008, 51(20):1944–1952.
19. Takigiku K, Takeuchi M, Izumi C, Yuda S, Sakata K, Ohte N, Tanabe K,
Nakatani S, on behalf of the JUSTICE investigators: Normal Range of Left
Ventricular 2-Dimensional Strain. Circ J 2012, Epud ahead of print.
20. Raimondi L, De Paoli P, Mannucci E, Lonardo G, Sartiani L, Banchelli G,
Pirisino R, Mugelli A, Cerbai E: Restoration of cardiomyocyte functional
properties by angiotensin II receptor blockade in diabetic rats. Diabetes
2004, 53:1927–1933.
21. Ng AC, Delgado V, Bertini M, van der Meer RW, Rijzewijk LJ, Hooi Ewe S,
Siebelink HM, Smit JW, Diamant M, Romijn JA, et al: Myocardial steatosis
and biventricular strain and strain rate imaging in patients with type 2
diabetes mellitus. Circulation 2010, 122:2538–2544.
22. Sacre JW, Franjic B, Jellis CL, Jenkins C, Coombes JS, Marwick TH:
Association of cardiac autonomic neuropathy with subclinical
myocardial dysfunction in type 2 diabetes. JACC Cardiovasc Imaging 2010,
3:1207–1215.
23. Jellis C, Wright J, Kennedy D, Sacre J, Jenkins C, Haluska B, Martin J,
Fenwick J, Marwick TH: Association of imaging markers of myocardial
fibrosis with metabolic and functional disturbances in early diabetic
cardiomyopathy. Circ Cardiovasc Imaging 2011, 6:693–702.
24. Andersson C, Gislason GH, Weeke P, Hoffmann S, Hansen PR,
Torp-Pedersen C, Søgaard P: Diabetes is associated with impaired
myocardial performance in patients without significant coronary artery
disease. Cardiovasc Diabetol 2010, 18:3.
25. Laakso M: Heart in diabetes: a microvascular disease. Diabetes Care 2011,
34(Supplement 2):S145–S149.
26. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A:
New type of cardiomyopathy associated with diabetic
glomerulosclerosis. Am J Cardiol 1972, 30:595–602.
27. Kawaguchi M, Techigawara M, Ishihata T, Asakura T, Saito F, Maehara K,
Maruyama Y: A comparison of ultrastructural changes on
endomyocardial biopsy specimens obtained from patients with
diabetes mellitus with and without hypertension. Hear Vessel 1997,
12:267–274.
28. De Lorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR: Prevalence and
prognostic value of perfusion defects detected by stress
technetium-99 m sestamibi myocardial perfusion single-photon
emission computed tomography in asymptomatic patients with
diabetes mellitus and no known coronary artery disease. Am J
Cardiol 2002, 90:827–832.
29. Hristov M, Erl W, Weber PC: Endothelial progenitor cells: mobilization,
differentiation, and homing. Arterioscler Thromb Vasc Biol 2003,
23:1185–1189.
30. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM,
Dimmeler S: Soluble factors released by endothelial progenitor cells
promote migration of endothelial cells and cardiac resident progenitor
cells. J Mol Cell Cardiol 2005, 39:733–742.
31. Yue WS, Lau KK, Siu CW, Wang M, Yan GH, Yiu KH, Tse HF: Impact of
glycemic control on circulating endothelial progenitor cells and arterial
stiffness in patients with type 2 diabetes mellitus. Cardiovasc Diabetol
2011, 10:113.
Zhao et al. Cardiovascular Diabetology 2012, 11:147 Page 8 of 8
http://www.cardiab.com/content/11/1/14732. Palombo C, Kozakova M, Morizzo C, Gnesi L, Barsotti MC, Spontoni P,
Massart F, Salvi P, Balbarini A, Saggese G, et al: Circulating endothelial
progenitor cells and large artery structure and function in young
subjects with uncomplicated type 1 diabetes. Cardiovasc Diabetol 2011,
10:88.
33. Yiu YF, Chan YH, Yiu KH, Siu CW, Li SW, Wong LY, Lee SW, Tam S, Wong EW,
Cheung BM, et al: Vitamin D deficiency is associated with depletion of
circulating endothelial progenitor cells and endothelial dysfunction in
patients with type 2 diabetes. J Clin Endocrinol Metab 2011, 96:E830–E835.
34. Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, Menegolo M,
de Kreutzenberg SV, Tiengo A, Agostini C, et al: Circulating endothelial
progenitor cells are reduced in peripheral vascular complications of type
2 diabetes mellitus. J Am Coll Cardiol 2005, 45:1449–1457.
35. Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M, Grego F,
Vigili de Kreutzenberg S, Tiengo A, Agostini C, et al: Number and function
of endothelial progenitor cells as a marker of severity for diabetic
vasculopathy. Arterioscler Thromb Vasc Biol 2006, 26(9):2140–2146.
36. Fadini GP, de Kreutzenberg S, Agostini C, Boscaro E, Tiengo A, Dimmeler S,
Avogaro A: Low CD34+ cell count and metabolic syndrome
synergistically increase the risk of adverse outcomes. Atherosclerosis 2009,
207:213–219.
37. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M,
Nickenig G: Circulating endothelial progenitor cells and cardiovascular
outcomes. N Eng J Med 2005, 353:999–1007.
38. Yeh ET, Zhang S, Wu HD, Körbling M, Willerson JT, Estrov Z:
Transdifferentiation of human peripheral blood CD34 + −enriched cell
population into cardiomyocytes, endothelial cells, and smooth muscle
cells in vivo. Circulation 2003, 108:2070–2073.
39. Fadini GP, de Kreutzenberg SV, Coracina A, Baesso I, Agostini C, Tiengo A,
Avogaro A: Circulating CD34+ cells, metabolic syndrome, and
cardiovascular risk. Eur Heart J 2006, 27:2247–2255.
40. Brownlee M: Biochemistry and molecular cell biology of diabetic
complications. Nature 2001, 414:813–820.
41. Huynh K, Kiriazis H, Du XJ, Love JE, Jandeleit-Dahm KA, Forbes JM,
McMullen JR, Ritchie RH: Coenzyme Q10 attenuates diastolic dysfunction,
cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse
model of type 2 diabetes. Diabetologia 2012, 55:1544–1553.
42. Khong FL, Zhang Y, Edgley AJ, Qi W, Connelly KA, Woodman OL, Krum H,
Kelly DJ: 30,40-Dihydroxyflavonol antioxidant attenuates diastolic
dysfunction and cardiac remodeling in streptozotocin-induced diabetic
m(Ren2)27 rats. PLoS One 2011, 6:e22777.
43. Hamed S, Brenner B, Aharon A, Daoud D, Roguin A: Nitric oxide and
superoxide dismutase modulate endothelial progenitor cell function in
type 2 diabetes mellitus. Cardiovasc Diabetol 2009, 8:56.
44. Ho SY: Anatomy and myoarchitecture of the left ventricular wall in
normal and in disease. Eur J Echocardiogr 2009, 10:iii3–iii7.
doi:10.1186/1475-2840-11-147
Cite this article as: Zhao et al.: Myocardial dysfunction in patients with
type 2 diabetes mellitus: role of endothelial progenitor cells and
oxidative stress. Cardiovascular Diabetology 2012 11:147.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
